Epivax Oncology specializes in precision cancer immunotherapy, utilizing advanced biomarker analysis to tailor treatments to individual patient profiles. This approach addresses the limitations of traditional one-size-fits-all cancer therapies by enhancing treatment efficacy and minimizing adverse effects.
Funding
$3.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional cancer therapies often follow a one-size-fits-all approach, which can lead to suboptimal treatment outcomes and increased adverse effects due to variations in individual patient profiles. The lack of personalized treatment strategies limits the effectiveness of these therapies for many patients.
Solution
EpiVax Therapeutics offers precision cancer immunotherapy by leveraging advanced biomarker analysis to tailor treatments to individual patient profiles. Their approach aims to enhance treatment efficacy and minimize adverse effects, addressing the limitations of traditional cancer therapies. By designing vaccines that activate the body's T cells, EpiVax Therapeutics seeks to cure or prevent disease in the host. The company's pipeline includes a personalized bladder cancer vaccine and a COVID-19 vaccine.
Target Audience
The primary target audience includes cancer patients seeking personalized treatment options and healthcare providers looking to improve treatment outcomes through precision medicine.
Features
- Advanced biomarker analysis for personalized treatment strategies
- Vaccine design to activate T cells for targeted immune response
- Focus on enhancing treatment efficacy and minimizing adverse effects
- Pipeline includes personalized bladder cancer vaccine
- Development of a COVID-19 vaccine